{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:15:32Z","timestamp":1790284532138,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K10653"],"award-info":[{"award-number":["JP24K10653"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K07417"],"award-info":[{"award-number":["JP21K07417"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K14789"],"award-info":[{"award-number":["JP23K14789"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030953","name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019702","name":"Tokyo Metropolitan Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24he2202020"],"award-info":[{"award-number":["JP24he2202020"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tjpad.2026.100567","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:39:02Z","timestamp":1775947142000},"page":"100567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-0634","authenticated-orcid":false,"given":"Masanori","family":"Kurihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-3283","authenticated-orcid":false,"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1085-5101","authenticated-orcid":false,"given":"Gen","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-4714","authenticated-orcid":false,"given":"Keiko","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-1932","authenticated-orcid":false,"given":"Taro","family":"Bannai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-732X","authenticated-orcid":false,"given":"Fumio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-7146","authenticated-orcid":false,"given":"Kenji","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1647-7229","authenticated-orcid":false,"given":"Ko","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Midori","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0001","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100567_bib0005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ggi.14945","article-title":"How will the emergence of lecanemab change dementia treatment?","volume":"24","author":"Iwata","year":"2024","journal-title":"Geriatr Gerontol Int"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0006","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"19","key":"10.1016\/j.tjpad.2026.100567_bib0007","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.tjpad.2026.100567_bib0008","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WAD.0000000000000239","article-title":"Evidence-based interpretation of amyloid-beta PET results: a clinician's tool","volume":"32","author":"Bergeron","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2026.100567_bib0010","article-title":"Patients\u2019 choices and eligibility for anti-amyloid therapy in Japan\u2019s universal insurance","volume":"18","author":"Ihara","year":"2026","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0011","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11604-025-01773-x","article-title":"Practical brain MRI guidelines for anti-abeta antibody treatment in early symptomatic Alzheimer\u2019s disease","volume":"43","author":"Kakeda","year":"2025","journal-title":"Jpn J Radiol"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100567_bib0012","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100567_bib0014","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","article-title":"Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease","volume":"36","author":"Imabayashi","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-240185","article-title":"Relationship between cerebrospinal fluid Alzheimer's Disease biomarker values measured via lumipulse assays and conventional ELISA: single-center experience and systematic review","volume":"99","author":"Kurihara","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100567_bib0016","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/acn3.51681","article-title":"Clinical utility of cerebrospinal fluid biomarkers measured by Lumipulse(R) system","volume":"9","author":"Nojima","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tjpad.2026.100567_bib0017","unstructured":"FDA. Evaluation of automatic class ill designation for lumipulse G \u03b2-amyloid ratio (1-42\/1-40) [July 31, 2023]."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40478-024-01758-3","article-title":"Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Abeta42 in Alzheimer's disease and other neurodegenerative diseases","volume":"12","author":"Kurihara","year":"2024","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100567_bib0019","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1212\/WNL.0000000000201647","article-title":"CSF P-Tau181 and other biomarkers in patients with neuronal intranuclear inclusion disease","volume":"100","author":"Kurihara","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41531-024-00806-y","article-title":"alpha-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with lewy body disease","volume":"10","author":"Kurihara","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100567_bib0021","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/acn3.70025","article-title":"Diagnostic challenge in frontal variant Alzheimer's disease with low amyloid-beta PET retention","volume":"12","author":"Shimasaki","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100567_bib0022","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100567_bib0023","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/brain\/awab248","article-title":"Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages","volume":"144","author":"Pascoal","year":"2021","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0024","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer's disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100567_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/RLU.0000000000005097","article-title":"Pitfalls of amyloid-beta PET: comparisons with 18 F-MK-6240 and 18 F-THK5351 PET","volume":"49","author":"Ishibashi","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0026","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/RLU.0000000000005842","article-title":"Both amyloid and tau assessments are desired before initiating disease-modifying therapy for Alzheimer disease: three real-world cases","volume":"50","author":"Ishibashi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0027","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100567_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100567_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40120-025-00756-4","article-title":"Characterizing the journey of early Alzheimer's disease in patients initiating Lecanemab treatment in the United States: a real-world evidence study","volume":"14","author":"Sabbagh","year":"2025","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100567_bib0032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00415-025-13059-3","article-title":"Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease","volume":"272","author":"Mittler","year":"2025","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease - the gateway to precision medicine","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100567_bib0035","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/cpt.2819","article-title":"Enhancing diversity and inclusion in clinical trials","volume":"113","author":"Corneli","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100567_bib0037","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0038","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","article-title":"Japanese and North American Alzheimer's disease neuroimaging initiative studies: harmonization for international trials","volume":"14","author":"Iwatsubo","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0039","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","article-title":"Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods","volume":"38","author":"Shang","year":"2024","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100567_bib0040","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early Alzheimer's Disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol Ther"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0041","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00259-019-04282-y","article-title":"Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?","volume":"46","author":"Farrar","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"10.1016\/j.tjpad.2026.100567_bib0042","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200148","article-title":"Spatial-temporal patterns of beta-amyloid accumulation: a subtype and stage inference model analysis","volume":"98","author":"Collij","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0043","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","article-title":"Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue","volume":"7","author":"Aguero","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2967\/jnumed.120.254961","article-title":"Direct comparison of the tau PET tracers (18)F-Flortaucipir and (18)F-MK-6240 in human subjects","volume":"63","author":"Gogola","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100567_bib0045","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","article-title":"Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease","volume":"82","author":"Pichet Binette","year":"2025","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100567_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213675","article-title":"Validating the amyloid cascade through the revised criteria of Alzheimer's association workgroup 2024 for Alzheimer disease","volume":"104","author":"Mendes","year":"2025","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100567_bib0047","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1002\/alz.14245","article-title":"Pilot implementation of the revised criteria for staging of Alzheimer's disease by the Alzheimer's Association Workgroup in a tertiary memory clinic","volume":"20","author":"Lu","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100567_bib0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.biopsych.2008.03.024","article-title":"Classification of white matter lesions on magnetic resonance imaging in elderly persons","volume":"64","author":"Kim","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-201213","article-title":"Alzheimer's Disease neuropathological comorbidities are common in the younger-old","volume":"79","author":"Beach","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0051","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1002\/alz.13858","article-title":"A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0052","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100567_bib0053","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100567_bib0054","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/alz.13658","article-title":"Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay","volume":"20","author":"Bellomo","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100567_bib0055","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1002\/alz.14225","article-title":"Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo","volume":"20","author":"Pichet Binette","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0056","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1002\/alz.13818","article-title":"alpha-synuclein seed amplification assay detects lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on lewy pathology burden","volume":"20","author":"Levin","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100567_bib0057","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1002\/alz.14276","article-title":"Association of CSF alpha-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer's disease neuroimaging initiative study","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100567_bib0058","article-title":"Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases","volume":"14","author":"Krishnadas","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0059","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100567_bib0060","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:42:48Z","timestamp":1780339368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2274580726000919"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100567","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100567"}}